Company Profile

Eiger Biopharmaceuticals LLC is a United States-based commercial-stage biopharmaceutical company. The Company is focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, and Peginterferon Lambda (lambda) for COVID-19. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Lambda is a type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections.

Employees

Sector

Biotechnology & Medical Research

More about the company

01/10/24	Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect	CI
30/09/24	Eiger BioPharmaceuticals, Inc. Went Out of Business	CI
05/09/24	Combined Hearing for Disclosure Statement and Plan Approved for Eiger BioPharmaceuticals, Inc.	CI
05/09/24	Fifth Amended Joint Liquidation Plan Filed by Eiger BioPharmaceuticals, Inc.	CI
04/09/24	First Motion for Exclusivity Period Extension Approved For Eiger BioPharmaceuticals, Inc.	CI
03/09/24	Fourth Amended Joint Liquidation Plan Filed by Eiger BioPharmaceuticals, Inc.	CI
02/09/24	Eiger InnoTherapeutics, Inc. acquired Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.	CI
02/09/24	Eiger InnoTherapeutics, Inc. acquired Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.	CI
02/09/24	Eiger InnoTherapeutics, Inc. completed the acquisition of Lonafarnib Antiviral Asset of Eiger BioPharmaceuticals, Inc. from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $5.2 million.	CI
28/08/24	Third Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.	CI
21/08/24	Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.	CI
15/08/24	Second Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.	CI
05/08/24	Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.	CI

29/08/23	Citigroup Adjusts Eiger BioPharmaceuticals Price Target to $3 From $4, Maintains Buy Rating	MT
30/06/23	Baird Adjusts Price Target on Eiger BioPharmaceuticals to $5 From $3, Maintains Outperform Rating	MT
07/09/22	BTIG Adjusts Eiger BioPharmaceuticals' Price Target to $48 from $57, Maintains Buy Rating	MT
11/10/21	Eiger BioPharmaceuticals : Wedbush Suspended Coverage on Eiger BioPharmaceuticals	MT
11/05/21	Eiger BioPharmaceuticals : Citigroup Adjusts Price Target on Eiger BioPharmaceuticals to $26 From $23, Maintains Buy Rating	MT

01/10/24	Eiger BioPharmaceuticals : DEBTOR AFFILIATES PURSUANT TO CHAPTER 11 OF THE BANKRUPTCY CODE Form 8 K	PU
16/07/24	Eiger BioPharmaceuticals : THIS IS NOT A SOLICITATION OF ACCEPTANCE OR REJECTION OF THE PLAN. THE DEBTORS ARE SEEKING APPROVAL OF THE DISCLOSURE STATEMENT ON A CONDITIONAL BASIS, BUT IT HAS NOT YET BEEN APPROVED BY THE BANKRUPTCY COURT Form 8 K	PU
11/07/24	Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist with FDA Breakthrough Therapy Designation	AQ
06/05/24	Sentynl Therapeutics Announces Global Acquisition of Zokinvy for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals	AQ
01/04/24	Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection	AQ

3 years	1.1	16
5 years	1.1	300.64
10 years	1.1	540

Manager	Title	Age	Since
Christopher Kurtz CTO	Chief Tech/Sci/R&D Officer	59	17/04/2022
Douglas Staut PRN	Corporate Officer/Principal	-	18/04/2024

Eiger BioPharmaceuticals Share Price

Stocks

EIGR

US28249U2042

Biotechnology & Medical Research

Latest news: Eiger BioPharmaceuticals

Analysts' recommendations: Eiger BioPharmaceuticals

Press Releases: Eiger BioPharmaceuticals

News in other languages: Eiger BioPharmaceuticals

Price Extremes

Managers and Directors: Eiger BioPharmaceuticals

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/10/23	Propel Bio Management LLC	Buy	Company	278,239	0.6281%
31/10/23	Propel Bio Management LLC	Buy	Company	24,332	0.0549%
18/10/23	Propel Bio Management LLC	Other	Company	5,096,986	11.5065%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EIGER BIOPHARMACEUTICALS	-.--%	-.--%	-	-	12.59M
WUXI APPTEC CO., LTD.	+0.79%	-6.16%	+49.32%	+74.50%	66.34B
LONZA GROUP AG	-0.54%	+6.05%	+11.17%	+89.50%	52.92B
ARGENX SE	-0.46%	+4.07%	+6.68%	+72.23%	54.82B
IQVIA HOLDINGS INC.	+0.74%	+2.75%	+26.31%	+45.29%	44.09B
BEONE MEDICINES AG	+3.87%	+10.15%	+20.69%	+132.73%	43.72B
REVOLUTION MEDICINES, INC.	+7.91%	+4.30%	+263.91%	+602.72%	42.13B
CELLTRION, INC.	-0.40%	+9.85%	+17.04%	+59.17%	33.96B
WUXI BIOLOGICS (CAYMAN) INC.	-1.54%	-0.92%	+36.81%	+6.78%	26.17B
GENMAB A/S	+0.31%	+5.20%	+36.08%	+25.90%	23.37B
Average	+1.07%	+1.67%	+52.00%	+123.20%	43.06B
Weighted average by Cap.	+1.26%	+1.99%	+51.09%	+128.05%